Leica Biosystems, part of Danaher, agreed to buy Statlab Medical Products to expand Leica’s diagnostics and anatomical pathology consumables and instrument offerings. Financial terms were not disclosed, but RBC Capital Markets analyst Dan Leonard estimated the deal could be worth more than $1 billion. For pathology operators, the acquisition could strengthen supply coverage for workflows spanning sample prep and slide-based testing, while broadening the product menu for labs managing increasing testing volumes and workflow complexity. The move also aligns with Danaher’s diagnostics strategy of consolidating adjacent parts of the pathology value chain. The transaction will likely be evaluated for integration synergies across instrument compatibility, distribution scale, and recurring consumable demand, depending on regulatory and commercial timing.